Výsledky vyhledávání

Akademický článek

Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019

Publikováno v: Breast Cancer Research, Vol 26, Iss 1, Pp 1-7 (2024)

Abstract Background Little is known about how use of chemotherapy has evolved in breast cancer patients. We therefore describe chemotherapy patterns for women with stage I-IIIA breast cancer in the Optimal Breast Cancer Chemotherapy Dosing (OBCD) Stu

Externí odkaz: https://doaj.org/article/e4df8f5cdae74a1a8836527359a19293

Zobrazit plný text záznamu

Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2

Autor: Blake T. Langlais, Mrinal M. Gounder, Ethan Basch, M. Petersen, Gary K. Schwartz, Narre Heon, Michelle R. Mahoney, Alexander J. Zoroufy, Amylou C. Dueck, Lauren J. Rogak, Gita Thanarajasingam, Brenda Ginos, Gina L. Mazza

Publikováno v: Quality of Life Research. 31:1069-1080

Purpose Missing scores complicate analysis of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) because patients with and without missing scores may systematically differ. We focus on optimal anal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e43f8b02f8dfe00dc433b6c45d5160d5
https://doi.org/10.1007/s11136-021-02968-1

Zobrazit plný text záznamu

Abstract P3-03-09: Assessment of Breast Cancer Chemotherapy Dose Reduction in an Integrated Healthcare Delivery System

Autor: Elizabeth D. Kantor, Kelli O’Connell, Isaac J. Ergas, Emily Valice, Janise M. Roh, Jenna Bhimani, Narre Heon, Jennifer J. Griggs, Jean Lee, Erin J. Bowles, Donna R. Rivera, Tatjana Kolevska, Elisa Bandera, Lawrence H. Kushi

Publikováno v: Cancer Research. 83:P3-03

Background: Most cytotoxic drugs are dosed according to body surface area (BSA), yet not all patients receive the full BSA-determined dose. Prior work suggests that dose reduction may occur more frequently in obese patients, likely due to concern abo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d29f4f80def27fdcf7115a37547154a
https://doi.org/10.1158/1538-7445.sabcs22-p3-03-09

Zobrazit plný text záznamu

Evaluating Treatment Tolerability Using the Toxicity Index With Patient-Reported Outcomes Data

Autor: Brenda Ginos, Gita Thanarajasingam, Gina L. Mazza, Patricia A. Ganz, Ethan Basch, Narre Heon, Blake T. Langlais, Gisela Schwab, Lauren J. Rogak, Amylou C. Dueck, Howard I. Scher

Publikováno v: Journal of pain and symptom management, vol 63, iss 2
J Pain Symptom Manage

Context Summarizing longitudinal symptomatic adverse events during clinical trials is necessary for understanding treatment tolerability. The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) provides

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65f841fef2db0e82873a951bc7eefd89
https://escholarship.org/uc/item/1d8536cm

Zobrazit plný text záznamu

Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2

Autor: Gina L, Mazza, Molly M, Petersen, Brenda, Ginos, Blake T, Langlais, Narre, Heon, Mrinal M, Gounder, Michelle R, Mahoney, Alexander J, Zoroufy, Gary K, Schwartz, Lauren J, Rogak, Gita, Thanarajasingam, Ethan, Basch, Amylou C, Dueck

Publikováno v: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 31(4)

Missing scores complicate analysis of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) because patients with and without missing scores may systematically differ. We focus on optimal analysis met

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e5009339adc41cc484b8065bc050fa0c
https://pubmed.ncbi.nlm.nih.gov/34635962

Zobrazit plný text záznamu

Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting

Autor: Thomas M. Atkinson, Mary Shaw, Lauren J. Rogak, Yuelin Li, Sean J. Ryan, Antonia V. Bennett, Narre Heon, Ethan Basch, Liora P. Stark

Publikováno v: Journal of Cancer Research and Clinical Oncology. 143:735-743

Symptomatic adverse event (AE) monitoring is essential in cancer clinical trials to assess patient safety, as well as inform decisions related to treatment and continued trial participation. As prior research has demonstrated that conventional concor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35bc031a4f0692688a2f69160be9974a
https://doi.org/10.1007/s00432-016-2335-9

Zobrazit plný text záznamu

Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Purpose The US National Cancer Institute (NCI) Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) was developed to enable patient reporting of symptomatic adverse events in oncology clinical research.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8026f524dd7b75b51926d93540373b0d
https://pubmed.ncbi.nlm.nih.gov/30204536

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání